Targeted Delivery of Small Interfering RNA: Approaching Effective Cancer Therapies
Abstract
Three of the primary requirements for the development of effective dual-targeting therapeutic modalities for the treatment of cancer are the tumor-targeted delivery of the therapeutic molecules of interest to the tumor site(s) in the body (both primary and metastatic), passage of the molecular therapeutic through the cell membrane, and targeting specifically a growth or apoptotic pathway. However, lack of efficient targeted delivery, low transfection efficiency, instability to nucleases, poor tissue penetration, and nonspecific immune stimulation have hindered the translation of small interfering RNA (siRNA) into clinical applications. The development of a systemically administered, tumor-specific immunoliposome nanocomplex with high transfection efficiency could overcome these limitations and thus realize the potential of siRNAs to become effective anticancer clinical modalities.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
RNAi has been employed preclinically and clinically in treatment of several types of disease including viruses and cancer, but has not been employed in stroke therapy.
“RNAi has been employed preclinically and clinically in treatment of several types of disease including viruses and cancer [26, 27], but has not been employed in stroke therapy.”
From MicroRNA‐21 protects neurons from ischemic death (2010) · cites this paper as [27]
Cited by
Sorted by citations
MicroRNA‐21 protects neurons from ischemic death
Buller, B., Liu, X., Wang, X., Zhang, R. L., Zhang, L., Hozeska‐Solgot, A., Chopp, M., & Zhang, Z. G. (2010) · The FEBS Journal · doi:10.1111/j.1742-4658.2010.07818.x · Cited by 242 · see citing works
Nanodelivery Systems for Nucleic Acid Therapeutics in Drug Resistant Tumors
Iyer, A. K., Duan, Z., & Amiji, M. M. (2014) · Molecular Pharmaceutics · doi:10.1021/mp500024p · Cited by 55 · see citing works
- Authors
- Pirollo, K. F., & Chang, E. H.
- Affiliations
- Georgetown University Medical Center (US)
- ORCID
- Chang, Esther H.
- Venue
- Cancer Research
- Published
- 2008-03-01
- Volume
- 68
- Issue
- 5
- Pages
- 1247-1250
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- OpenAlex
- W2031432800
- Cited by
- 121
- References
- 0
- Citations by year
- 2026: 1 · 2024: 2 · 2023: 1 · 2022: 1 · 2021: 2 · 2020: 2 · 2019: 3 · 2018: 1 · 2017: 3 · 2016: 3 · 2015: 5 · 2014: 7 · 2013: 17 · 2012: 15
- FWCI
- 7.79
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Physical Sciences › Engineering › Biomedical Engineering › Ultrasound and Hyperthermia Applications
- Keywords
- siRNA, targeted delivery, cancer therapy, immunoliposomes, nanocomplexes, transfection efficiency, tumor targeting, metastatic cancer, nucleic acid stability, tissue penetration, immunostimulation, apoptosis signaling, siRNA therapeutics
- MeSH terms
- Animals, Humans, Neoplasm Metastasis, Neoplasm Transplantation, Neoplasms, Peptides, Genetic Therapy, Gene Transfer Techniques, RNA, Small Interfering, Nanotechnology, Mice, Nanoparticles
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
